Diphenidol
| File:Diphenidol.svg | |
| Gene therapy | |
|---|---|
| Clinical data | |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Oral |
| ATC code |
|
| Physiological data | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 4 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem Template:Abbreviation | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H27NO |
| Molar mass | 309.44518 g/mol |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
|
WikiDoc Resources for Diphenidol |
|
Articles |
|---|
|
Most recent articles on Diphenidol |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Diphenidol at Clinical Trials.gov Clinical Trials on Diphenidol at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Diphenidol
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Diphenidol Discussion groups on Diphenidol Patient Handouts on Diphenidol Directions to Hospitals Treating Diphenidol Risk calculators and risk factors for Diphenidol
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Diphenidol |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Diphenidol is an muscarinic antagonist employed as an antiemetic and as an antivertigo agent. It is currently not marketed in the United States or Canada.
References
DrugBank http://www.drugbank.ca/drugs/DB01231